Guidelines for Dosing and Monitoring of Low-Molecular Weight Heparin (LMWH)
Contents
- General dosing guidelines (pdf)
- LMWH order form (pdf)
- Short term monitoring
- Long term monitoring
- Use in pregnancy
Short Term Monitoring Guidelines
- Baseline PT/aPTT
- Baseline hematocrit (then prn if bleeding is suspected or confirmed
- Baseline platelet count, and q2-3 days during first 2 weeks of LMWH therapy
- Baseline serum creatinine, and q7days, (then prn if change in renal function is suspected, or if bleeding is suspected or confirmed)
Long Term Monitoring Guidelines
| Patient weight | q1-3 months and adjust LMWH dose if needed |
| Platelet count | q1-3 months |
| Hematocrit | q1-3 months |
| Serum creatinine/CrCl | q1-3 months (and PRN if change in renal function is suspected or if bleeding is suspected or confirmed) and adjust LMWH dose if needed |
| Trough antiXa level |
|
Use in Pregnancy
- 1st and 2nd Trimester
| Patient weight | q1 month and adjust LMWH dose if needed |
| Platelet count | q1 month |
| Hematocrit | q1 month |
| Serum creatinine/CrCl | q1 month and adjust LMWH dose if needed |
| Trough antiXa level |
|
- 3rd Trimester
| Patient weight | q2 weeks |
| Platelet count | q2 weeks |
| Hematocrit | q2 weeks |
| Serum creatinine/CrCl | q2 weeks and adjust LMWH dose if needed |
| Trough antiXa level |
|
| Peak antiXa level |
|
- Peak antiXa Dosing Adjustments
| Peak antiXa level (units/mL) | Hold next dose | Dosage change | Next antiXa Level |
|---|---|---|---|
| <0.35 | No | Increase 25% | 4hrs after next dose |
| 0.35-0.49 | No | Increase 10% | 4hrs after next dose |
| 0.5-1 | No | None | Next day, then within 1 week |
| 1.1-1.5 | No | Decrease 20% | Before next dose |
| 1.6-2 | For 3hrs | Decrease 30% | Before next dose and 4hrs after next dose |
| >2 | Until antiXa level <0.5 | Decrease 40% | Before next dose and q12h until antiXa level <0.5 units/mL |